ArticleBMC cancer2018
'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.Thoracic cancer · 2020Pooled it
- T cell subsets in cervical cancer tumor microenvironment: advances and therapeutic opportunities.Frontiers in immunology · 2025Review
- Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.Scientific reports · 2023Article
- Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.Journal of clinical medicine · 2022Review
- PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.Frontiers in oncology · 2022Review
- Chemo-immunoablation of solid tumors: A new concept in tumor ablation.Frontiers in immunology · 2022Review
- The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.Journal of clinical medicine · 2021Review
- Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights.International journal of molecular sciences · 2021Review
- Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.Frontiers in immunology · 2021Review
- A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer.Molecular therapy oncolytics · 2020Article
- ASF1B promotes cervical cancer progression through stabilization of CDK9.Cell death & disease · 2020Article
- The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.International journal of molecular sciences · 2020Review
- Higher T cell immunoglobulin mucin-3 (Tim-3) expression in cervical cancer is associated with a satisfactory prognosis.Translational cancer research · 2020Article
- Cervical Cancer: Emerging Immune Landscape and Treatment.OncoTargets and therapy · 2020Review
- Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy.Cancer management and research · 2020Article
- Unlocking the therapeutic potential of primary tumor-draining lymph nodes.Cancer immunology, immunotherapy : CII · 2019Review
- The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer.International journal of molecular sciences · 2019Review
- Efficacy of PD-1 blockade in cervical cancer is related to a CD8Journal for immunotherapy of cancer · 2019Article
- Human Papillomavirus Type 16 Disables the Increased Natural Killer Cells in Early Lesions of the Cervix.Journal of immunology research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTreatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current systemic treatment often causes autoimmune side effects. In more than 50% of squamous cell cervical cancer, PD-L1 expression is detected. Moreover, we observed high and interrelated rates of PD-L1 positive macrophages and regulatory T cells in metastatic lymph nodes of cervical cancer patients. As cervical cancer in general initially metastasizes to regional lymph nodes, local administration of durvalumab (a PD-L1 checkpoint inhibitor) at an early stage will deliver these antibodies exactly where they are needed, facilitating immune protection. This may result in a clinical benefit while reducing undesirable side effects.
methodsDURVIT is a non-randomized, single-arm, open-label, phase I study. Three escalating dose levels of intratumourally (i.t.) injected durvalumab will be tested, i.e. 5, 10 and 20 mg (three patients per dose level, with an additional three at the highest tolerated dose). The primary endpoint of this phase-I study is safety. Immune monitoring will consist of flow cytometric, immunohistochemical and functional T cell reactivity testing. The first patient has been included in this trial in November 2017. DISCUSSION: Evidence of safety and biological efficacy of this locally administered checkpoint blockade may expand adjuvant therapy options for cervical cancer patients. Early metastatic spread of cervical cancer cells may thus be controlled in the draining lymph node basin, and beyond, and hopefully delay or even prevent the onset of disease recurrence.
trial registrationNTR6119 , 1-nov-2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.